(VIANEWS) – Apache (APA), Priority Technology Holdings (PRTH), United Therapeutics Corporation (UTHR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Apache (APA)
22% sales growth and 121.63% return on equity
APA Corporation, an independent energy company, explores for, develops, and produces natural gas, crude oil, and natural gas liquids. It has oil and gas operations in the United States, Egypt, and North Sea. The company also has exploration and appraisal activities in Suriname, as well as holds interests in projects located in Uruguay and internationally. APA Corporation was incorporated in 1954 and is headquartered in Houston, Texas.
Earnings Per Share
As for profitability, Apache has a trailing twelve months EPS of $9.25.
PE Ratio
Apache has a trailing twelve months price to earnings ratio of 3.64. Meaning, the purchaser of the share is investing $3.64 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 121.63%.
Volume
Today’s last reported volume for Apache is 5096460 which is 26.8% below its average volume of 6962460.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jul 22, 2024, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 3.28%.
Moving Average
Apache’s value is higher than its 50-day moving average of $32.09 and below its 200-day moving average of $35.43.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 30.6% and a drop 17.3% for the next.
2. Priority Technology Holdings (PRTH)
18.1% sales growth and 3.76% return on equity
Priority Technology Holdings, Inc. operates as a payment technology company in the United States. It operates through three segments: Small and Medium-Sized Businesses (SMB) Payments, Business-To-Business Payments, and Enterprise Payments. The company offers MX product line, including MX Connect and MX Merchant products, such as MX Insights, MX Storefront, MX Retail, MX Invoice, MX B2B and ACH.com, and others, which provides flexible and customizable set of business applications that helps to manage critical business work functions and revenue performance to resellers and merchant clients using core payment processing as our leverage point. It also offers CPX, a platform that offers accounts payable automation solutions, including virtual card, purchase card, ACH +, dynamic discounting, or check. In addition, the company provides curated managed services and a suite of integrated accounts payable automation solutions to various financial institutions and card networks; and payment-adjacent technologies to facilitate the acceptance of electronic payments from customers. Further, it offers embedded payment and banking solutions to enterprise customers to modernize legacy platforms and accelerate software partners' strategies to monetize payments; and managed services solutions that provide audience-specific programs for institutional partners and other third parties; and consulting and development solutions. The company serves SMB, and enterprises, as well as distribution partners, including retail and wholesale independent sales organizations, financial institutions, and independent software vendors. Priority Technology Holdings, Inc. was founded in 2005 and is headquartered in Alpharetta, Georgia.
Earnings Per Share
As for profitability, Priority Technology Holdings has a trailing twelve months EPS of $-0.58.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.76%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 62.5% and 87.5%, respectively.
Volume
Today’s last reported volume for Priority Technology Holdings is 212227 which is 367.61% above its average volume of 45385.
Sales Growth
Priority Technology Holdings’s sales growth for the next quarter is 18.1%.
3. United Therapeutics Corporation (UTHR)
15.1% sales growth and 20.08% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $21.12.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 12.99. Meaning, the purchaser of the share is investing $12.99 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 20.08%.
4. PulteGroup (PHM)
9.9% sales growth and 27.3% return on equity
PulteGroup, Inc., through its subsidiaries, primarily engages in the homebuilding business in the United States. It acquires and develops land primarily for residential purposes; and constructs housing on such land. The company also offers various home designs, including single-family detached, townhomes, condominiums, and duplexes under the Centex, Pulte Homes, Del Webb, DiVosta Homes, American West, and John Wieland Homes and Neighborhoods brand names. As of December 31, 2022, it controlled 211,112 lots, of which 108,848 were owned and 102,264 were under land option agreements. In addition, the company arranges financing through the origination of mortgage loans primarily for homebuyers; sells the servicing rights for the originated loans; and provides title insurance policies, and examination and closing services to homebuyers. The company was founded in 1950 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, PulteGroup has a trailing twelve months EPS of $12.47.
PE Ratio
PulteGroup has a trailing twelve months price to earnings ratio of 9.29. Meaning, the purchaser of the share is investing $9.29 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.3%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.4%, now sitting on 16.44B for the twelve trailing months.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 18, 2024, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 0.71%.
5. Genmab (GMAB)
9.6% sales growth and 18.32% return on equity
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.96.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 30.48. Meaning, the purchaser of the share is investing $30.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.32%.
Moving Average
Genmab’s value is above its 50-day moving average of $29.17 and below its 200-day moving average of $31.19.
6. Otter Tail Corporation (OTTR)
9.3% sales growth and 22.17% return on equity
Otter Tail Corporation, together with its subsidiaries, engages in electric utility, manufacturing, and plastic pipe businesses in the United States. The company's Electric segment produces, transmits, distributes, and sells electric energy in Minnesota, North Dakota, and South Dakota; and operates as a participant in the Midcontinent Independent System Operator, Inc. markets. This segment generates electricity through coal, wind and hydro, and natural gas. It serves approximately 133,000 residential, industrial, and other commercial customers. Its Manufacturing segment engages in the contract machining, metal parts stamping, fabrication and painting, and production of plastic thermoformed horticultural containers, life science and industrial packaging, and material handling components, and extruded raw material stock for recreational vehicle, agricultural, construction, lawn and garden, and industrial and energy equipment industries. It also manufactures clamshell packing, blister packs, returnable pallets, and handling trays for shipping and storing odd-shaped or difficult-to-handle parts for customers in the horticulture, medical and life sciences, industrial, recreation, and electronics industries. The company's Plastics segment manufactures polyvinyl chloride pipes for municipal water, rural water, wastewater, storm drainage and water reclamation system, and other uses. This segment markets its products to wholesalers and distributors through independent sales representatives, company salespersons, and customer service representatives. The company was formerly known as Otter Tail Power Company and changed its name to Otter Tail Corporation in 2001. Otter Tail Corporation was founded in 1907 and is headquartered in Fergus Falls, Minnesota.
Earnings Per Share
As for profitability, Otter Tail Corporation has a trailing twelve months EPS of $7.28.
PE Ratio
Otter Tail Corporation has a trailing twelve months price to earnings ratio of 12.66. Meaning, the purchaser of the share is investing $12.66 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.17%.
Yearly Top and Bottom Value
Otter Tail Corporation’s stock is valued at $92.16 at 01:22 EST, below its 52-week high of $99.49 and way above its 52-week low of $68.96.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 13.3% and a negative 20.5%, respectively.
Moving Average
Otter Tail Corporation’s value is above its 50-day moving average of $85.50 and way above its 200-day moving average of $82.86.
7. CrossFirst Bankshares (CFB)
8.4% sales growth and 10.11% return on equity
CrossFirst Bankshares, Inc. operates as the bank holding company for CrossFirst Bank that provides various banking and financial services to businesses, business owners, professionals, and its personal networks. The company offers commercial real estate, construction and land development, 1-4 family real estate, multifamily real estate, commercial and industrial, energy, and consumer loans. It also provides a range of deposit products consisting of non-interest-bearing demand and interest-bearing deposits, which include transaction accounts, savings accounts, money market accounts, and certificates of deposit; and personal and business checking and savings accounts, as well as negotiable order of withdrawal accounts; and brokered and reciprocal deposits. In addition, the company offers international banking services; treasury management services; automated teller machine access; and mobile banking services. Further, it holds investments in marketable securities. It has full-service banking offices in Kansas, Missouri, Oklahoma, Arizona, Colorado, New Mexico, and Texas. CrossFirst Bankshares, Inc. was founded in 2007 and is headquartered in Leawood, Kansas.
Earnings Per Share
As for profitability, CrossFirst Bankshares has a trailing twelve months EPS of $1.37.
PE Ratio
CrossFirst Bankshares has a trailing twelve months price to earnings ratio of 9.74. Meaning, the purchaser of the share is investing $9.74 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.11%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 2.9% and a negative 2.7%, respectively.
Sales Growth
CrossFirst Bankshares’s sales growth is 5.8% for the present quarter and 8.4% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4%, now sitting on 233.32M for the twelve trailing months.
8. U.S. Physical Therapy (USPH)
8.3% sales growth and 6.47% return on equity
U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The company operates through two segments, Physical Therapy Operations and Industrial Injury Prevention Services. It offers industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. The company was founded in 1990 and is based in Houston, Texas.
Earnings Per Share
As for profitability, U.S. Physical Therapy has a trailing twelve months EPS of $1.16.
PE Ratio
U.S. Physical Therapy has a trailing twelve months price to earnings ratio of 88.42. Meaning, the purchaser of the share is investing $88.42 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.47%.
